Drug Shortages: FDA Says Market Must Reward Production Quality
FDA officials state in journal article that manufacturers are not incentivized to ensure quality and base competition entirely on price.
You may also be interested in...
US FDA task force recommends a rating system that purchasers could rely on to reward manufacturers with robust management systems.
Firms that manufacture sterile drugs on traditional filling lines instead of using restricted access barriers or isolators risk tighter scrutiny from FDA inspectors, agency official says. Yet it remains unclear how much of a difference the increased oversight will make.
The Office of Generic Drugs may evolve to focus more on clinical issues as the new Office of Pharmaceutical Quality creates uniform standards for manufacturing process engineering and other production areas, the CDER director says in an interview.